A Phase 3 interventional study of NT 201 and NT 201 Placebo in Neuromuscular Agents, Peripheral Nervous System Agents and Physiological Effects of Drugs, sponsored by Merz Aesthetics GmbH. Active, not recruiting at 26 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Merz Aesthetics GmbH (part of Merz Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).
Merz Aesthetics GmbH is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive NT 201 IM injection, once on Day 1 of the MP.
Drug: NT 201
Participants will receive NT 201 matching placebo IM injection, once on Day 1 of the MP.
Drug: NT 201 Placebo
Participants will receive a reinjection of NT 201 IM injection, once on Day 1 of OLEX period.
Drug: NT 201
Clostridium Botulinum neurotoxin A (150 kiloDalton \[kD\], free of complexing proteins), powder for solution for injection.
Also known as: IncobotulinumtoxinA, Xeomin/Bocouture, Xeomin Cosmetic, Xeomeen
NT 201 matching-placebo.
Composite Achievement of Grade 1 or Grade 2 and at Least a 2-Grade Improvement From Baseline Based on Both the Investigator's Assessment and Participant's Self-Assessment Using the Merz Aesthetics Platysma Scale Dynamic (MAPSD) At Week 2 of MP
MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.
Time frame: At Week 2 of MP
Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on the Investigator's Assessment Using MAPSD at Week 2 of MP
MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.
Time frame: At Week 2 of MP
Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on the Participant's Self-Assessment Using MAPSD at Week 2 of MP
MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.
Time frame: At Week 2 of MP
Achievement of at Least a +1 (Somewhat Satisfied) Score Using the Participant's Satisfaction Questionnaire at Week 2 of MP
Participants satisfaction questionnaire responses will be rated on a scale ranging from +3 (very satisfied) to -3 (very dissatisfied). A higher score indicates satisfaction.
Time frame: At Week 2 of MP
Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on Both the Investigator's Assessment and Participant's Self-Assessment Using MAPSD at Week 1 and Week 4 up to Week 17 of MP
MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.
Time frame: At Week 1 and Week 4 up to Week 17 of MP
Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on the Investigator's Assessment Using MAPSD at Week 1 and Week 4 up to Week 17 of MP
MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.
Time frame: At Week 1 and Week 4 up to Week 17 of MP
Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on Participant's Self-Assessment Using MAPSD at Week 1 and Week 4 up to Week 17 of MP
MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.
Time frame: At Week 1 and Week 4 up to Week 17 of MP
Achievement of at Least a +1 (Improved) Score on the Global Aesthetic Improvement Scale (GAIS)-Platysmal Bands at maximum contraction Based on the Investigator's Assessment at Week 2 of MP
GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.
Time frame: At Week 2 of MP
Achievement of at Least a +1 (Improved) Score on the GAIS-Platysmal Bands at maximum contraction Based on the Participant's Self-Assessment at Week 2 of MP
GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.
Time frame: At Week 2 of MP
Achievement of at Least a +1 (Improved) Score on the GAIS-Platysmal Bands at Rest Based on the Investigator's Assessment at Week 2 of MP
GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.
Time frame: At Week 2 of MP
Achievement of at Least a +1 (Improved) Score on the GAIS-Platysmal Bands at Rest Based on the Participant's Self-Assessment at Week 2 of MP
GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.
Time frame: At Week 2 of MP
Achievement of at Least a +1 (Improved) Score Using the GAIS-Lower Face Contour According to the Investigator's Assessment at Week 2 of MP
GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.
Time frame: At Week 2 of MP
Achievement of at Least a +1 (Improved) Score Using the GAIS-Lower Face Contour According to the Participant's Self-Assessment at Week 2 of MP
GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.
Time frame: At Week 2 of MP
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Aug 2026, 10 months.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Aug 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: incobotulinumtoxinA